Cargando…

Mutations in BRCA2 and taxane resistance in prostate cancer

Mutations in BRCA1 or BRCA2 define a subset of prostate cancer patients. Herein, we address the question whether BRCA1/2 mutations have a predictive impact on chemotherapy with docetaxel, a widely used drug in patients with metastatic castration resistant prostate cancer (mCRPC). Fifty-three men tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nientiedt, Cathleen, Heller, Martina, Endris, Volker, Volckmar, Anna-Lena, Zschäbitz, Stefanie, Tapia-Laliena, María A., Duensing, Anette, Jäger, Dirk, Schirmacher, Peter, Sültmann, Holger, Stenzinger, Albrecht, Hohenfellner, Markus, Grüllich, Carsten, Duensing, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496866/ https://www.ncbi.nlm.nih.gov/pubmed/28676659 http://dx.doi.org/10.1038/s41598-017-04897-x

Ejemplares similares

The BRCA2 mutation status shapes the immune phenotype of prostate cancer
por: Jenzer, Maximilian, et al.
Publicado: (2019)

Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy
por: Dietz, Steffen, et al.
Publicado: (2017)

Prospective single center trial of next-generation sequencing analysis in metastatic renal cell cancer: the MORE-TRIAL
por: Dieffenbacher, Svenja, et al.
Publicado: (2018)

Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery
por: Li, Jielin, et al.
Publicado: (2021)

Genomic features of renal cell carcinoma with venous tumor thrombus
por: Warsow, Gregor, et al.
Publicado: (2018)

Digital Spatial Profiling Identifies the Tumor Periphery as a Highly Active Biological Niche in Clear Cell Renal Cell Carcinoma
por: Schneider, Felix, et al.
Publicado: (2023)

BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study
por: Friedhoff, Jana, et al.
Publicado: (2022)

Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers
por: Zschäbitz, Stefanie, et al.
Publicado: (2017)

Cullin 5 is a novel candidate tumor suppressor in renal cell carcinoma involved in the maintenance of genome stability
por: Tapia-Laliena, María Ángeles, et al.
Publicado: (2019)

Harnessing the p53-PUMA Axis to Overcome DNA Damage Resistance in Renal Cell Carcinoma()
por: Zhou, Xiaoguang, et al.
Publicado: (2014)

Senescent Tumor Cells Are Frequently Present at the Invasion Front: Implications for Improving Disease Control in Patients with Locally Advanced Prostate Cancer
por: Schwarz, Sebastian, et al.
Publicado: (2023)

Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity
por: Hoefflin, Rouven, et al.
Publicado: (2016)

Impact of Surgeon’s Experience in Rigid versus Elastic MRI/TRUS-Fusion Biopsy to Detect Significant Prostate Cancer Using Targeted and Systematic Cores
por: Görtz, Magdalena, et al.
Publicado: (2022)

Bortezomib: killing two birds with one stone in gastrointestinal stromal tumors
por: Duensing, Stefan, et al.
Publicado: (2010)

An artificial intelligence-based chatbot for prostate cancer education: Design and patient evaluation study
por: Görtz, Magdalena, et al.
Publicado: (2023)

Next-generation sequencing facilitates detection of the classic E13-A20 EML4-ALK fusion in an ALK-FISH/IHC inconclusive biopsy of a stage IV lung cancer patient: a case report
por: Volckmar, Anna-Lena, et al.
Publicado: (2016)

Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies
por: Christopoulos, Petros, et al.
Publicado: (2021)

MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker
por: Macher-Goeppinger, Stephan, et al.
Publicado: (2016)

miR-449a Repression Leads to Enhanced NOTCH Signaling in TMPRSS2:ERG Fusion Positive Prostate Cancer Cells
por: Bauer, Simone, et al.
Publicado: (2021)

Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK(+) Lung Cancer Patients with Poor Survival
por: Christopoulos, Petros, et al.
Publicado: (2019)

Kidney Cancer Models for Pre-Clinical Drug Discovery: Challenges and Opportunities
por: Pohl, Laura, et al.
Publicado: (2022)

Daughter Centriole Elongation Is Controlled by Proteolysis
por: Korzeniewski, Nina, et al.
Publicado: (2010)

The ribosomal protein S6 in renal cell carcinoma: functional relevance and potential as biomarker
por: Knoll, Maximilian, et al.
Publicado: (2015)

Uncoupling of PUMA Expression and Apoptosis Contributes to Functional Heterogeneity in Renal Cell Carcinoma — Prognostic and Translational Implications()
por: Zhou, Xiaoguang, et al.
Publicado: (2015)

Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate
por: Apostolidis, Leonidas, et al.
Publicado: (2019)

Publisher Correction: Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder
por: Tosev, Georgi, et al.
Publicado: (2021)

Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder
por: Tosev, Georgi, et al.
Publicado: (2021)

A novel role of the aryl hydrocarbon receptor (AhR) in centrosome amplification - implications for chemoprevention
por: Korzeniewski, Nina, et al.
Publicado: (2010)

Efficacy and Safety of Checkpoint Inhibitor Treatment in Patients with Advanced Renal or Urothelial Cell Carcinoma and Concomitant Chronic Kidney Disease: A Retrospective Cohort Study
por: Seydel, Florian, et al.
Publicado: (2021)

Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer
por: Elsayed, Mei, et al.
Publicado: (2021)

Soluble histone H2AX is induced by DNA replication stress and sensitizes cells to undergo apoptosis
por: Liu, Ying, et al.
Publicado: (2008)

Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1–ALK-rearranged lung cancer
por: Dietz, Steffen, et al.
Publicado: (2019)

Biomarkers for the Detection and Risk Stratification of Aggressive Prostate Cancer
por: Eickelschulte, Samaneh, et al.
Publicado: (2022)

Survival outcomes of patients with germ cell tumors treated with high-dose chemotherapy for refractory or relapsing disease
por: Zschäbitz, Stefanie, et al.
Publicado: (2018)

Correlation between genomic index lesions and mpMRI and (68)Ga-PSMA-PET/CT imaging features in primary prostate cancer
por: Kesch, Claudia, et al.
Publicado: (2018)

Ioncopy: an R Shiny app to call copy number alterations in targeted NGS data
por: Budczies, Jan, et al.
Publicado: (2018)

Gamma-tubulin and 53BP1 as candidate biomarkers of human papillomavirus-associated anal dysplasia
por: Ho, Ken S, et al.
Publicado: (2010)

Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA
por: Dietz, Steffen, et al.
Publicado: (2020)

RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples
por: Kirchner, Martina, et al.
Publicado: (2019)

Ago-RIP-Seq identifies Polycomb repressive complex I member CBX7 as a major target of miR-375 in prostate cancer progression
por: Pickl, Julia M.A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_m5mhiijbv3g8fm7ng7o1rh90iu